XD14

Cat. No.:	HY-110215
CAS No.:	1370888-71-3
Molecular Formula:	$C_{20}H_{27}N_3O_5S$
Molecular Weight:	421.51
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (296.55 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3724 mL	11.8621 mL	23.7242 mL
	5 mM	0.4745 mL	2.3724 mL	4.7448 mL
	10 mM	0.2372 mL	1.1862 mL	2.3724 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.93 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.93 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

XD14 is a potent BET inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with K_ds of 170, 380, and 160 nM, respectively[1].

IC_{50} & Target	BRD2	BRD3	BRD4
	170 nM (Kd)	380 nM (Kd)	160 nM (Kd)

REFERENCES

[1]. Schäker-Hübner L, et al. 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads. J Med Chem. 2021 Oct 14;64(19):14620-14646.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA